Protocol Ledger

NCT05164172 · Phase III · RECRUITING

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Interventional Phase III clinical trial protocol NCT05164172 sponsored by H. Lundbeck in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-01 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05164172
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05164172
Protocol FieldVerified Registry Value
NCT IdentifierNCT05164172
Consolidated Lead SponsorH. Lundbeck
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2021-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05164172
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI